Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies

Frontiers in Neurology

Volumn APR, Issue , 2012, Pages

  Almeida, Maria do Rosário ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Glucocerebrosidase gene; Lewy body pathology; Parkinson disease; Synucleinopathies

Indexed keywords

EID: 84865855443     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2012.00065     Document Type: Article

References (71)

1. Aharon-Peretz, J., Rosenbaum, H., and Gershoni-Baruch, R. (2004). Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashke-nazi Jews. N. Engl. J. Med. 351, 1972-1977.
2. Amato, D., Stachiw, T., Clarke, J. T., and Rivard, G. E. (2004). Gaucher disease: variability in phenotype among siblings. J. Inherit. Metab. Dis. 27, 659-669.
3. Anheim, M., Elbaz, A., Lesage, S., Durr, A., Condroyer, C., Viallet, F., Pollak, P., Bonaïti, B., Bonaïti-Pellié, C., and Brice, A. on behalf of the French Parkinson Disease Genetic Group. (2012). Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78, 417-420.
4. Argov, Z., and Navon, R. (1984). Clinical and genetic variations in the syndrome of adult GM2 gangliosi-dosis resulting from hexosaminidase A deficiency. Ann. Neurol. 16, 14-20.
5. Bembi, B., Zambito Marsala, S., Sidran-sky, E., Ciana, G., Carrozzi, M., Zor-zon, M., Martini, C., Gioulis, M., Pittis, M. G., and Capus, L. (2003). Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 61, 99-101.
6. Beutler, E., and Grabowski, G. A. (2001). " Gaucher disease," in The Metabolic and Molecular Bases of Inherited Disease, 8th Edn, eds C. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle (New York: McGraw-Hill), 3635-3668.
7. Brady, R. O., Kanfer, J., and Shapiro, D. (1965). The metabolism of glu-cocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J. Biol. Chem. 240, 39-43.
8. Bras, J., Paisan-Ruiz, C., Guerreiro, R., Ribeiro, M. H., Morgadinho, A., Jan-uario, C., Sidransky, E., Oliveira, C., and Singleton, A. (2009). Complete screening for glucocerebrosi-dase mutations in Parkinson disease patients from Portugal. Neurobiol. Aging 30, 1515-1517.
9. Bras, J., Singleton, A., Cookson, M. R., and Hardy,J. (2008). Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J. 275, 5767-5773.
10. Capablo, J. L., Saenz de Cabezón, A., Fraile, J., Alfonso, P., Pocovi, M., and Giraldo, P. on behalf of the Spanish Group on Gaucher Disease. (2008). Neurological evaluation of patients with Gaucher disease diagnosed as type 1. J. Neurol. Neurosurg. Psychiatr. 79, 219-222.
11. Clark, L. N., Kartsaklis, L. A., Wolf Gilbert, R., Dorado, B., Ross, B. M., Kisselev, S., Verbitsky, M., Mejia-Santana, H., Cote, L. J., Andrews, H., Vonsattel, J. P., Fahn, S., Mayeux, R., Honig, L. S., and Marder, K. (2009). Association of glucocere-brosidase mutations with dementia with lewy bodies. Arch. Neurol. 66, 578-583.
12. Cox, T. M., and Schofield, J. P. (1997). Gaucher's disease: clinical features and natural history. Baillieres Clin. Haematol. 10, 657-689.
13. Cuervo, A. M., Stefanis, L., Freden-burg, R., Lansbury, P. T., and Sulzer, D. (2004). Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295.
14. Cullen, V., Sardi, S. P., Ng, J., Xu, Y. H., Sun,Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., Rochet, J. C., Glicksman, M. A., Cheng, S. H., Grabowski, G. A., Shihabuddin, L. S., and Schlossmacher, M. G. (2011). Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69, 940-953.
15. Dahl, N., Lagerström, M., Erikson, A., and Pettersson, U. (1990). Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosi-dase gene. Am. J. Hum. Genet. 47, 275-278.
16. De Marco, E. V., Annesi, G., Taran-tino, P., Rocca, F. E., Provenzano, G., Civitelli, D., Cirò Candiano, I. C., Annesi, F., Carrideo, S., Condino, F., Nicoletti, G., Messina, D., Nov-ellino, F., Morelli, M., and Quat-trone, A. (2008). Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov. Disord. 23, 460-463.
17. De Paolo, J., Goker-Alpan, O., Samad-dar, T., Lopez, G., and Sidransky, E. (2009). The association between mutations in the lysosomal protein glucocerebrosidase and parkinson-ism. Mov. Disord. 24, 1571-1578.
18. Farrer, M. J., Williams, L. N., Algom, A. A., Kachergus, J., Hulihan, M. M., Ross, O. A., Rajput, A., Papa-petropoulos, S., Mash, D. C., and Dickson, D. W. (2009). Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat. Disord. 15, 414-416.
19. Gitler, A. D., Chesi, A., Geddie, M. L., Strathearn, K. E., Hamamichi, S., Hill, K. J., Caldwell, K. A., Cald-well, G. A., Cooper, A. A., Rochet, J. C., and Lindquist, S. (2009). Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41, 308-315.
20. Goker-Alpan, O., Giasson, B. I., Eblan, M. J., Nguyen, J., Hurtig, H. I., Lee, V. M., Trojanowski, J. Q., and Sidran-sky, E. (2006). Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 67, 908-910.
21. Goker-Alpan, O., Lopez, G., Vithayathil, J., Davis, J., Hallett, M., and Sidran-sky, E. (2008). The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch. Neurol. 65, 1353-1357.
22. Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R., McInerney-Leo, A., and Sidransky, E. (2004). Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41, 937-940.
23. Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I., and Sidransky, E. (2010). Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 120, 641-649.
24. Halperin, A., Elstein, D., and Zimran, A. (2003). Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol. Dis. 36, 426-428.
25. Horowitz, M., Wilder, S., Horowitz, Z., Reiner, O., Gelbart, T., and Beutler, E. (1989). The human glucocerebrosi-dase gene and pseudogene: structure and evolution. Genomics 4, 87-96.
26. Hruska, K. S., LaMarca, M. E., Scott, C. R., and Sidransky, E. (2008). Gaucher disease: mutation and polymorphism spectrum in the glu-cocerebrosidase gene (GBA). Hum. Mutat. 29, 567-583.
27. Inzelberg, R., and Korczyn, A. D. (1994). Parkinsonism in adult-onset GM2 gangliosidosis. Mov. Disord. 9, 375-377.
28. Jamrozik, Z., Lugowska, A., Slawek, J., and Kwiecinski, H. (2009). Glu-cocerebrosidase mutations p.L444P and p.N370S are not associated with multisystem atrophy, progressive supranuclear palsy and cor-ticobasal degeneration in Polish patients. J. Neurol. 257, 459-460.
29. Kalinderi, K., Bostantjopoulou, S., Paisan-Ruiz, C., Katsarou, Z., Hardy, J., and Fidani, L. (2009). Complete screening for glucocerebrosi-dase mutations in Parkinson disease patients from Greece. Neurosci. Lett. 452, 87-89.
30. Kaplan, P., Andersson, H. C., Kacena, K. A., and Yee, J. D. (2006). The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch. Pediatr. Adolesc. Med. 160, 603-608.
31. Kono, S., Ouchi, Y., Terada, T., Ida, H., Suzuki, M., and Miyajima, H. (2010). Functional brain imaging in glucocerebrosidase mutation carriers with and without Parkinsonism. Mov. Disord. 25, 1823-1829.
32. Lachmann, R. H., Grant, I. R., Halsall, D., and Cox, T. M. (2004). Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM 97, 199-204.
33. Lesage, S., Anheim, M., Condroyer, C., Pollak, P., Durif, F., Dupuits, C.,Vial-let, F., Lohmann, E., Corvol, J. C., Honoré, A., Rivaud, S., Vidailhet, M., Dürr, A., and Brice, A. for the French Parkinson's Disease Genetics Study Group. (2010). Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum. Mol. Genet. 20, 202-210.
34. Lu, C. S., Lai, S. C., Wu, R. M., Weng, Y. H., Huang, C. L., Chen, R. S., Chang, H. C., Wu-Chou, Y. H., and Yeh, T. H. (2012). PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 183-191.
35. Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M. E., and Sidransky, E. (2004). Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81, 70-73.
36. Machaczka, M., Rucinska, M., Skot-nicki, A. B., and Jurczak, W. (1999). Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am. J. Hematol. 61, 216-217.
37. Manning-Bog, A. B., Schule, B., and Langston, J. W. (2009). Alpha-synuclein glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30, 1127-1132.
38. Mata, I. F., Samii, A., Schneer, S. H., Roberts, J. W., Griffith, A., Leis, B. C., Schellenberg, G. D., Sidransky, E., Bird, T. D., Leverenz, J. B., Tsuang, D., and Zabetian, C. P. (2008). Gluco-cerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch. Neurol. 65, 379-382.
39. Mazzulli, J. R., Xu, Y. H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., and Krainc, D. (2011). Gaucher disease glucocerebrosidase and a-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52.
40. Mitsui, J., Mizuta, I., Toyoda, A., Ashida, R., Takahashi, Y., Goto, J., Fukuda, Y., Date, H., Iwata, A., Yamamoto, M., Hattori, N., Murata, M., Toda, T., and Tsuji, S. (2009). Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch. Neurol. 66, 571-576.
41. Muthane, U., Chickabasaviah, Y., Kane-ski, C., Shankar, S. K., Narayanappa, G., Christopher, R., and Govin-dappa, S. S. (2004). Clinical features of adult GM1 gangliosidosis: report of three Indian patients and review of 40 cases. Mov. Disord. 19, 1334-1341.
42. Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., and Zimran, A. (1996). Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89, 691-694.
43. Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lach-mann, R. H., Li, A., Holton, J., Guer-reiro, R., Paudel, R., Segarane, B., Singleton, A., Lees, A., Hardy, J., Houlden, H., Revesz, T., and Wood, N. W. (2009). Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783-1794.
44. Nichols, W. C., Pankratz, N., Marek, D. K., Pauciulo, M. W., Elsaesser, V. E., Halter, C. A., Rudolph, A., Wojcieszek, J., Pfeiffer, R. F., and Foroud, T. for the Parkinson Study Group-PROGENI Investigators. (2009). Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72, 310-316.
45. Nishioka, K., Ross, O. A.,Vilariño-Güell, C., Cobb, S. A., Kachergus, J. M., Mann, D. M., Snowden, J., Richardson, A. M., Neary, D., Robinson, C. A., Rajput, A., Papapetropoulos, S., Mash, D. C., Pahwa, R., Lyons, K. E., Wszolek, Z. K., Dickson, D. W., and Farrer, M. J. (2011). Glucocerebrosi-dase mutations in diffuse Lewy body disease. Parkinsonism Relat. Disord. 17, 55-57.
46. Orimo, S., Iwasaki, T., Yoshino, H., Arai, M., and Hiyamuta, E. (1994). Na autopsied case of Fabry's disease presenting with parkinsonism and car-diomegaly as a cardinal clinical manifestation. Rinsho Shinkeigaku 34, 1003-1007.
47. Orvisky, E., Park, J. K., LaMarca, M. E., Ginns, E. I., Martin, B. M., Tayebi, N., and Sidransky, E. (2002). Gluco-sylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab.76, 262-270.
48. Paisán-Ruiz, C., Li, A., Schneider, S. A., Holton, J. L., Johnson, R., Kidd, D., Chataway, J., Bhatia, K. P., Lees, A. J., Hardy,J.,Revesz, T., and Houlden, H. (2012). Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neu-robiol. Aging 33, 814-823.
49. Ron, I., Rapaport, D., and Horowitz, M. (2010). Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum. Mol. Genet. 19, 3771-3781.
50. Roze, E., Paschke, E., Lopez, N., Eck, T., Yoshida, K., Maurel-Ollivier, A., Doummar, D., Caillaud, C., Galanaud, D., Billette de Villemeur, T., Vidailhet, M., and Roubergue, A. (2005). Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov. Disord. 20, 1366-1369.
51. Saito, Y., Suzuki, K., Hulette, C. M., and Murayama, S. (2004). Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. J. Neuropathol. Exp. Neurol. 63, 323-328.
52. Schapira, A. H. (2011). Mitochondrial pathology inParkinson's disease.Mt. Sinai J. Med. 78, 872-881.
53. Schapira, A. H., and Gegg, M. (2011). Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis. 2011, 159160.
54. Schultz, M. L., Tecedor, L., Chang, M., and Davidson, B. L. (2011). Clarifying lysosomal storage diseases. Trends Neurosci. 34, 401-410.
55. Setó-Salvia, N., Pagonabarraga, J., Houlden, H., Pascual-Sedano, B., Dols-Icardo, O., Tucci, A., Paisán-Ruiz, C., Campolongo, A., Antón-Aguirre, S., Martín, I., Muñoz, L., Bufill, E., Vilageliu, L., Grinberg, D., Cozar, M., Blesa, R., Lleó, A., Hardy, J., Kulisevsky, J., and Clarimón J. (2011). Glucocerebrosi-dase mutations confer a greater risk of dementia during Parkinson's disease course. Mov. Disord. 27, 393-399.
56. Settembre, C., Fraldi, A., Jahreiss, L., Spampanato, C., Venturi, C., Medina, D., de Pablo, R., Tacchetti, C., Rubinsztein, D. C., and Ballabio, A. (2008). A block of autophagy in lyso-somal storage disorders. Hum. Mol. Genet. 17, 119-129.
57. Shachar, T., Lo Bianco, C., Recchia, A., Wiessner, C., Raas-Rothschild, A., and Futerman, A. H. (2011). Lyso-somal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 26, 1593-1604.
58. Shi, C. H., Tang, B. S., Wang, L., Lv, Z. Y., Wang, J., Luo, L. Z., Shen, L., Jiang, H., Yan, X. X., Pan, Q., Xia, K., and Guo, J. F. (2011). PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort. Neurology 77, 75-81.
59. Sidransky, E. (2004). Gaucher disease: complexity in a " simple" disorder. Mol. Genet. Metab. 83, 6-15.
60. Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Bar-bosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C. M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr,A.,Eblan, M. J.,Fahn,S.,Farrer, M. J., Fung, H. C.,Gan-Or, Z.,Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G. J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E. K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Witt-stock, M., Wolfsberg, T. G., Wu,Y. R., Zabetian, C. P., Zhao, Y., and Ziegler, S. G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661.
61. Tayebi, N., Walker, J., Stubblefield, B., Orvisky, E., LaMarca, M. E., Wong, K., Rosenbaum, H., Schiffmann, R., Bembi, B., and Sidransky, E. (2003). Gaucher disease with parkinson-ian manifestations: does glucocere-brosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab. 79, 104-109.
62. Toft, M., Pielsticker, L., Ross, O. A.,Aasly, J. O., and Farrer, M. J. (2006). Glu-cocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 66, 415-417.
63. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., and Shen, J. (2010). Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U.S.A. 107, 9879-9884.
64. Velayati, A., Yu, W. H., and Sidransky, E. (2010). The role of glucocerebrosi-dase mutations in Parkinson disease and Lewy body disorders. Curr. Neurol. Neurosci. Rep. 10, 190-198.
65. Wenning, G. K., Stefanova, N., Jellinger, K. A., Poewe, W., and Schlossmacher, M. G. (2008). Multiple system atrophy: a primary oligodendrogliopa-thy. Ann. Neurol. 64, 239-246.
66. Westbroek, W., Gustafson, A. M., and Sidransky, E. (2011). Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol. Med. 17, 485-493.
67. Winder-Rhodes, S. E., Garcia-Reitböck, P., Ban, M., Evans, J. R., Jacques, T. S., Kemppinen, A., Foltynie, T., Williams-Gray, C. H., Chin-nery, P. F., Hudson, G., Burn, D. J., Allcock, L. M., Sawcer, S. J., Barker, R. A., and Spillantini, M. G. (2012). Genetic and pathological links between Parkinson's disease and the lysosomal disorder San-filippo syndrome. Mov. Disord. 27, 312-315.
68. Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G. D., Wake-field, L. K., Morrison, A., Lwin, A., Colegial, C., Allman, J. M., and Schiffmann, R. (2004). Neu-ropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82, 192-207.
69. Wong, K., Topaloglu, H., Tresser, N., and Schiffmann, R. (2000). Dementia with Lewy bodies and Parkinson's disease in a type 1 Gaucher disease patient. J. Neuropathol. Exp. Neurol. 59, 141.
70. Xu, Y. H., Sun, Y., Ran, H., Quinn, B., Witte, D., and Grabowski, G. A. (2010). Accumulation and distribution of alpha-synuclein and ubiqui-tin in the CNS of Gaucher disease mouse models. Mol. Genet. Metab. 102, 436-437.
71. Yap, T. L., Gruschus, J. M., Velay-ati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., and Lee, J. C. (2011). Alpha-synuclein interacts with lucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 286, 28080-28088